Is a
Clinical Study attributes
NCT Number
Trial Recruitment Size
250
Trial Sponsor
Clinical Trial Start Date
October 31, 2011
0Primary Completion Date
January 4, 2013
0Study Completion Date
January 4, 2013
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Treatment0
Intervention Type
Drug0
Intervention Name
rhGAA0
duvoglustat0
Interventional Trial Phase
Phase 20
Official Name
An Open-Label, Multi-Center, International Study to Investigate Drug-Drug Interactions Between AT2220 and Alglucosidase Alfa in Patients With Pompe Disease0
Last Updated
October 2, 2018
0Allocation Type
Non-Randomized0
Intervention Model
Parallel Assignment0
Masking Type
None (Open Label)0
Study summary
This study evaluates drug-drug interactions between AT2220 (duvoglustat) and recombinant human alpha-glucosidase (rhGAA, also known as alglucosidase alfa) in participants with Pompe Disease.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
